Definium Therapeutics (NASDAQ:DFTX) Lowered to Sell Rating by Wall Street Zen

Definium Therapeutics (NASDAQ:DFTX) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Several other research firms also recently commented on DFTX. Oppenheimer set a $60.00 price objective on shares of Definium Therapeutics and gave the company an “outperform” rating in a report on Monday, June 22nd. Royal Bank Of Canada restated an “outperform” rating on shares of Definium Therapeutics in a research report on Monday, June 22nd. Citigroup restated a “buy” rating on shares of Definium Therapeutics in a research report on Monday, June 22nd. Canaccord Genuity Group set a $58.00 price target on Definium Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Finally, Piper Sandler reiterated an “overweight” rating and set a $48.00 price objective (down from $49.00) on shares of Definium Therapeutics in a research note on Friday, May 8th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Definium Therapeutics currently has a consensus rating of “Buy” and an average price target of $49.23.

Definium Therapeutics Trading Up 0.4%

Definium Therapeutics stock opened at $44.29 on Friday. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.15. Definium Therapeutics has a 52 week low of $7.96 and a 52 week high of $49.20. The company has a market capitalization of $4.42 billion, a price-to-earnings ratio of -17.79 and a beta of 2.20. The stock has a 50-day moving average price of $31.43 and a 200 day moving average price of $22.77.

Definium Therapeutics (NASDAQ:DFTX) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.23). Sell-side analysts anticipate that Definium Therapeutics will post -2.27 EPS for the current year.

Insider Activity

In related news, insider Matthew T. Wiley sold 2,867 shares of the stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $129,101.01. Following the sale, the insider directly owned 174,633 shares of the company’s stock, valued at approximately $7,863,723.99. This represents a 1.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Mark Sullivan sold 13,008 shares of the firm’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $585,750.24. Following the sale, the insider owned 320,571 shares in the company, valued at approximately $14,435,312.13. This represents a 3.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 48,096 shares of company stock worth $2,165,763 over the last 90 days. Company insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Palumbo Wealth Management LLC boosted its stake in shares of Definium Therapeutics by 18.4% during the 4th quarter. Palumbo Wealth Management LLC now owns 39,002 shares of the company’s stock worth $522,000 after acquiring an additional 6,073 shares in the last quarter. Flagship Harbor Advisors LLC acquired a new stake in shares of Definium Therapeutics during the 4th quarter valued at about $117,000. Bay Rivers Group increased its stake in shares of Definium Therapeutics by 14.3% in the 4th quarter. Bay Rivers Group now owns 16,001 shares of the company’s stock valued at $214,000 after purchasing an additional 2,000 shares in the last quarter. FNY Investment Advisers LLC purchased a new position in shares of Definium Therapeutics in the 3rd quarter valued at about $107,000. Finally, Caxton Associates LLP acquired a new position in Definium Therapeutics in the 3rd quarter worth about $126,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.